Login / Signup

The pediatric solid organ transplant experience with COVID-19: An initial multi-center, multi-organ case series.

Matthew Benjamin GossN Thao N GalvánWenly RuanFlor M MunozEileen D BrewerChristine A O'MahonyErnestina Melicoff-PortilloWilliam J DreyerTamir A MilohFrancisco G CigarroaDaniel RanchDor YoeliMegan A AdamsSarah KoohmaraieDiana M HarterAbbas A RanaRonald T CottonBeth CarterShreena PatelNicolas Fernando MorenoDaniel H LeungJohn A Goss
Published in: Pediatric transplantation (2020)
The clinical course of COVID-19 in pediatric solid organ transplant recipients remains ambiguous. Though preliminary experiences with adult transplant recipients have been published, literature centered on the pediatric population is limited. We herein report a multi-center, multi-organ cohort analysis of COVID-19-positive transplant recipients ≤ 18 years at time of transplant. Data were collected via institutions' respective electronic medical record systems. Local review boards approved this cross-institutional study. Among 5 transplant centers, 26 patients (62% male) were reviewed with a median age of 8 years. Six were heart recipients, 8 kidney, 10 liver, and 2 lung. Presenting symptoms included cough (n = 12 (46%)), fever (n = 9 (35%)), dry/sore throat (n = 3 (12%)), rhinorrhea (n = 3 (12%)), anosmia (n = 2 (8%)), chest pain (n = 2 (8%)), diarrhea (n = 2 (8%)), dyspnea (n = 1 (4%)), and headache (n = 1 (4%)). Six patients (23%) were asymptomatic. No patient required supplemental oxygen, intubation, or ECMO. Eight patients (31%) were hospitalized at time of diagnosis, 3 of whom were already admitted for unrelated problems. Post-transplant immunosuppression was reduced for only 2 patients (8%). All symptomatic patients recovered within 7 days. Our multi-institutional experience suggests the prognoses of pediatric transplant recipients infected with COVID-19 may mirror those of immunocompetent children, with infrequent hospitalization and minimal treatment, if any, required.
Keyphrases